Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Antiviral treatment for HBV lowers the risk for liver cancer and other complications and can prevent transmission.
However, researchers saw little difference across racial groups in HBV treatment initiation among those who were eligible.
Generic drugs are cheaper and lead to better treatment compliance compared with brand-name drugs.
Most people who stopped long-term nucleoside/nucleotide analogs did not need to restart treatment.
Researchers have challenged findings from a Chinese study that concluded Baraclude is tied to a lower risk of liver cancer.
New research shows that treating these viruses can reduce liver cancer risk.
People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.
South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.
The drug is still associated with a lower liver cancer rate than Baraclude.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
Tenofovir was associated with a lower risk of hepatocellular carcinoma, but this might be related to other factors as well.
Researchers analyzed a cohort of South Koreans taking Viread (tenofovir disoproxil fumarate) or Baraclude (entecavir) for hepatitis B.
This includes a higher risk of liver cancer, cirrhosis-related complications and death.
The exception is those people with hepatitis B and liver cancer.
However, no such difference was seen among those with cirrhosis or those whose virus was not well treated.
Treatment with Viread and Baraclude led to a decline in liver cancer in Europe but not in South Korea.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.